Last reviewed · How we verify
NCT05817188
Medication Repurposing to Stop Cognitive Decline in Dementia
trial testing No intervention in Alzheimer Dementia in 100,000 participants. Completed in 1 March 2025.
1 March 2025
Quick facts
| Lead sponsor | Karolinska Institutet |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100,000 |
| Start date | 1 January 2023 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- No intervention
Conditions studied
- Alzheimer Dementia — all drugs for Alzheimer Dementia →
- Dementia Disorders — all drugs for Dementia Disorders →
Sponsor
Karolinska Institutet
Who can join
40 and older, any sex, with Alzheimer Dementia or Dementia Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. Many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia. Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has \>100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination-MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. The investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. The investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05817188
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Alzheimer Dementia
Currently open trials in the same condition.
- NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting
- NCT07222280 — Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy · NA · recruiting
- NCT04838301 — Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease · Phase 2 · recruiting
- NCT03926520 — Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) · NA · recruiting
- NCT04289402 — Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease · NA · active not recruiting
Other Karolinska Institutet trials
Trials by the same sponsor.
- NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
- NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
- NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
- NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
- NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05817188 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
- Last refreshed: 2 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05817188.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing